...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International clinical psychopharmacology >Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.
【24h】

Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.

机译：等效剂量的依他普仑和西酞普兰具有相似的疗效吗？对重度抑郁症的两项阳性安慰剂对照研究的汇总分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Escitalopram is the S-enantiomer of citalopram. In this study, we compared the efficacy of equivalent dosages of escitalopram and citalopram in the treatment of moderate to severe major depressive disorder (MDD), based on data from two, pooled, randomized, double-blind, placebo-controlled studies of escitalopram in which citalopram was the active reference. The primary efficacy parameter was the mean change from baseline in the Montgomery Asberg Depression Rating Scale (MADRS) total score. Significant differences in favour of escitalopram were observed for the MADRS [P<0.05, observed cases (OC)/last observation carried forward (LOCF)] and Clinical Global Improvement-Severity of Illness scores (CGI-S; P<0.05, OC/LOCF). Escitalopram separated from placebo at week 1 on the primary efficacy parameter, whereas citalopram first separated from placebo at week 6. An analysis of time to response showed that escitalopram-treated patients responded significantly faster to treatment than citalopram-treated patients (P<0.01). More patients responded to and achieved remission with escitalopram than to citalopram (P<0.05, OC). The HAMD scale was only used in the fixed-dose study, where escitalopram-treated patients had a significant reduction in HAMD-17 total score at week 8 compared to citalopram-treated patients (P<0.05, OC/LOCF). In the pooled subpopulation of severely ill patients (MADRS>/=30), escitalopram-treated patients showed greater improvement than citalopram-treated patients (P<0.05, LOCF/OC). Escitalopram showed consistently superior efficacy compared to citalopram in the treatment of moderate to severe MDD on all efficacy parameters, and was similarly well tolerated.
机译：依西酞普兰是西酞普兰的S-对映体。在这项研究中，我们根据两项依西酞普兰的合并，随机，双盲，安慰剂对照研究的数据，比较了依西酞普兰和西酞普兰当量剂量治疗中度至重度严重抑郁症（MDD）的疗效。哪个西酞普兰是积极的参考。主要功效参数是蒙哥马利·阿斯伯格抑郁量表（MADRS）总分与基线的平均变化。观察到MADRS对依他普仑的支持率存在显着差异[P <0.05，观察病例（OC）/结转末次观察（LOCF）]和临床总体疾病改善程度评分（CGI-S; P <0.05，OC / LOCF）。在主要疗效参数上，依西酞普兰在第1周从安慰剂中分离出来，而西酞普兰在第6周时首先从安慰剂中分离出来。对反应时间的分析表明，依西酞普兰治疗的患者对治疗的反应显着快于西酞普兰治疗的患者（P <0.01） 。与依他普仑相比，接受依他普仑治疗的患者多于西酞普兰（P <0.05，OC）。 HAMD量表仅用于固定剂量研究，与西酞普兰治疗的患者相比，依西酞普兰治疗的患者在第8周的HAMD-17总得分显着降低（P <0.05，OC / LOCF）。在重症患者的合并亚群中（MADRS> / = 30），依西酞普兰治疗的患者比西酞普兰治疗的患者表现出更大的改善（P <0.05，LOCF / OC）。在所有功效参数上，艾司西酞普兰在治疗中度至重度MDD方面均显示出比西酞普兰一致的优越疗效，并且耐受性相似。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号